Targeting KRAS G12C in NSCLC

KRAS – specifically, advanced NSCLC with a KRAS G12C mutation, has emerged as a unique area of research for a select group of oncologists. To help us understand what these mutations mean, Lung Cancer Considered host Dr. Stephen Liu interviewed two leading thoracic medical oncologists in the field: Dr. Melissa Johnson, the Program Director of Lung Cancer Research at the Sarah Cannon Research Institute and Dr. Ferdinandos Skoulidis, an Associate Professor at the University of Texas MD Anderson Cancer Center.